Reuters reports that GlaxoSmithKline, Britain’s largest pharmaceutical manufacturer, has filed for approval of a diabetes drug called albiglutide in both the United States and Europe.
The story says albiglutide is among a class of medicines that increase GLP-1, which is a hormone that stimulates insulin production from the pancreas.
A recent study found two other diabetes drugs in that class, Merck’s Januvia and Bristol-Myers Squibb’s Byetta, may double the risk of a ...
continue reading...